Pulmonary exacerbations in cystic fibrosis: Young children with characteristic signs and symptoms

被引:41
|
作者
Regelmann, Warren E. [1 ]
Schechter, Michael S. [2 ,3 ]
Wagener, Jeffrey S. [4 ]
Morgan, Wayne J. [5 ]
Pasta, David J. [6 ]
Elkin, Eric P. [6 ]
Konstan, Michael W. [7 ,8 ]
机构
[1] Univ Minnesota, Dept Pediat, Minneapolis, MN 55455 USA
[2] Emory Univ, Dept Pediat, Atlanta, GA 30322 USA
[3] Childrens Healthcare Atlanta, Atlanta, GA USA
[4] Univ Colorado Denver, Sch Med, Dept Pediat, Aurora, CO USA
[5] Univ Arizona, Dept Pediat, Tucson, AZ 85721 USA
[6] ICON Late Phase & Outcomes Res, San Francisco, CA USA
[7] Rainbow Babies & Childrens Hosp, Dept Pediat, Cleveland, OH 44106 USA
[8] Case Western Reserve Univ, Sch Med, Cleveland, OH USA
关键词
cough; crackles; cystic fibrosis; sputum; weight decline; TOBRAMYCIN;
D O I
10.1002/ppul.22658
中图分类号
R72 [儿科学];
学科分类号
100202 ;
摘要
Background A standard definition of pulmonary exacerbation based on signs and symptoms would be useful for categorizing cystic fibrosis (CF) patients and as an outcome measure of therapy. The frequently used definition of treatment with intravenous antibiotics varies with practice patterns. One approach to this problem is to use large data sets which include a patient's signs and symptoms along with their clinician's decision to treat with antibiotics for the diagnosis of pulmonary exacerbation. Previous analysis of such a data set, the Epidemiologic Study of Cystic Fibrosis (ESCF), found that new crackles, increased cough, increased sputum, and weight decline were the four clinical characteristics most strongly influencing providers to treat young CF patients for a pulmonary exacerbation. The objectives of this study were to confirm that these four characteristics influence the decision to treat with antibiotics for a pulmonary exacerbation in young CF patients; to evaluate their implications for future nutritional status and lung function; and to assess the effect of antibiotic treatment on these characteristic signs and symptoms. Methods This was an observational, longitudinal cohort study of clinical care in children <6 years old cared for at sites participating in ESCF. Results Using data from children not included in the previous ESCF study, we confirmed that these four characteristics were significantly associated with the likelihood of physicians prescribing antibiotics to treat a pulmonary exacerbation. The number of these characteristics present at a single clinic visit before age 6 predicted hospitalization rate over the next year, the weight-for-age z-score, and the forced expiratory volume in 1sec (FEV1) percent predicted at age 7. Treatment with antibiotics was associated with a greater decrease in the proportion of children with crackles, cough, and Pseudomonas aeruginosa at a follow-up visit within 6 months. Conclusions New crackles, increased cough, increased sputum, and decline in weight percentile at a single clinic visit increase the risk of future malnutrition, hospitalization, and airflow obstruction in young children with CF. Treatment with antibiotics mitigates some of these signs and symptoms by the first follow-up visit. The presence of these four characteristic signs and symptoms is useful to define pulmonary exacerbations in young children with CF that respond to antibiotic treatment in the short-term and influence long-term prognosis. Pediatr Pulmonol. 2013; 48:649-657. (c) 2012 Wiley Periodicals, Inc.
引用
收藏
页码:649 / 657
页数:9
相关论文
共 50 条
  • [1] Bronchiectasis and Pulmonary Exacerbations in Children and Young Adults With Cystic Fibrosis
    Loeve, Martine
    Gerbrands, Krista
    Hop, Wim C.
    Rosenfeld, Margaret
    Hartmann, Ieneke C.
    Tiddens, Harm A.
    CHEST, 2011, 140 (01) : 178 - 185
  • [2] Pulmonary Exacerbations in Children with Cystic Fibrosis
    Waters, Valerie
    Ratjen, Felix
    ANNALS OF THE AMERICAN THORACIC SOCIETY, 2015, 12 : S200 - S206
  • [3] Outpatient management of pulmonary exacerbations in children with cystic fibrosis
    Perrem, Lucy
    Martin, Isaac
    Ratjen, Felix
    EXPERT REVIEW OF RESPIRATORY MEDICINE, 2023, 17 (04) : 295 - 304
  • [4] Bronchodilator Response in Children with Cystic Fibrosis Pulmonary Exacerbations
    Pollak, M.
    Wilson, D.
    Klingel, M.
    Solomon, M.
    Grasemann, H.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2019, 199
  • [5] UTILITY OF THE LUNG CLEARANCE INDEX TO MONITOR PULMONARY EXACERBATIONS IN YOUNG CHILDREN WITH CYSTIC FIBROSIS
    Webster, H.
    Pizarro, M.
    McDonald, N.
    Jensen, R.
    Klingel, M.
    Stanojevic, S.
    Davis, S. D.
    Retsch-Bogart, G. Z.
    Pittman, J. E.
    Subbarao, P.
    Ratjen, F.
    PEDIATRIC PULMONOLOGY, 2015, 50 : 282 - 282
  • [6] Pulmonary exacerbations in cystic fibrosis
    Stenbit, Antine E.
    Flume, Patrick A.
    CURRENT OPINION IN PULMONARY MEDICINE, 2011, 17 (06) : 442 - 447
  • [7] Pulmonary exacerbations in cystic fibrosis
    Rabin, HR
    Butler, SM
    Wohl, MEB
    Geller, DE
    Colin, AA
    Schidlow, DV
    Johnson, CA
    Konstan, MW
    Regelmann, WE
    PEDIATRIC PULMONOLOGY, 2004, 37 (05) : 400 - 406
  • [8] Cystic fibrosis pulmonary exacerbations
    Ferkol, T
    Rosenfeld, M
    Milla, CE
    JOURNAL OF PEDIATRICS, 2006, 148 (02): : 259 - 264
  • [9] Reduction of pulmonary exacerbations in young children with cystic fibrosis during the COVID-19 pandemic
    Patel, Shreya
    Thompson, Misty D.
    Slaven, James E.
    Sanders, Don B.
    Ren, Clement L.
    PEDIATRIC PULMONOLOGY, 2021, 56 (05) : 1271 - 1273
  • [10] Special considerations for the treatment of pulmonary exacerbations in children with cystic fibrosis
    Waters, Valerie
    Stanojevic, Sanja
    Ratjen, Felix
    EXPERT REVIEW OF RESPIRATORY MEDICINE, 2016, 10 (11) : 1221 - 1228